Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

Delayed Quote. Delayed  - 09/28 03:36:41 pm
78.85 CHF   +0.96%
07:16a NOVARTIS : Sandoz invites young entrepreneurs to enter Sandoz HACk, ..
09/27 XENCOR : grows in San Diego
09/26 NOVARTIS : receives three new FDA approvals for the expanded use of ..
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
09/22/2016 09/23/2016 09/26/2016 09/27/2016 09/28/2016 Date
79.25(c) 79.15(c) 78(c) 78.1(c) 78.85 Last
4 428 711 4 589 639 4 268 468 4 700 893 2 147 583 Volume
+0.38% -0.13% -1.45% +0.13% +0.96% Change
More quotes
Financials ($)
Sales 2016 48 892 M
EBIT 2016 11 365 M
Net income 2016 7 821 M
Debt 2016 14 753 M
Yield 2016 3,53%
Sales 2017 50 225 M
EBIT 2017 12 172 M
Net income 2017 8 545 M
Debt 2017 13 988 M
Yield 2017 3,72%
P/E ratio 2016 23,28
P/E ratio 2017 21,29
EV / Sales2016 4,63x
EV / Sales2017 4,50x
Capitalization 211 785 M
More Financials
Company
Novartis AG develops, manufactures, and markets healthcare products.It operates through the following segments: Pharmaceuticals, Alcon, Sandoz, and Corporate Activities.The Pharmaceuticals segment provides patent-protected prescription medicines.The Alcon segment offers surgical, ophthalmic... 
Sector
Pharmaceuticals
Calendar
10/25Earnings Release
More about the company
Surperformance© ratings of Novartis AG
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVARTIS AG
07:16a NOVARTIS : Sandoz invites young entrepreneurs to enter Sandoz HACk, a global com..
09/27 XENCOR : grows in San Diego
09/26 NOVARTIS : receives three new FDA approvals for the expanded use of Ilaris treat..
09/26 NOVARTIS : announces positive top-line results from ASCEND-4, a Phase III trial ..
09/26 NOVARTIS : Nouscom Appoints New Chief Operating Officer and Strengthens the Boar..
09/23 NOVARTIS : receives three new FDA approvals for the expanded use of Ilaris treat..
09/23 NOVARTIS : Alcon Research Assigned Patent
09/23 NOVARTIS : announces positive top-line results from ASCEND-4, a Phase III trial ..
09/22 DOES NOVARTIS AG (NYSE : NVS) Have The Solution For Malaria?
09/22 NOVARTIS : Pharma star celebrates two special anniversaries
More news
Sector news : Pharmaceuticals - NEC
02:13p Monsanto ally Novozymes sees opportunity, risk in Bayer merger
09/27DJPFIZER : Scraps Plan to Break Up Company -- WSJ
09/26DJMYLAN : EpiPen Pretax Profits 60% Higher Than Number Told to Congress -- 3rd Upd..
09/26 MYLAN : faces scrutiny over EpiPen profit data shown to Congress
09/26DJPFIZER : Throws Out Plan to Split Into Two Companies -- 2nd Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
09/27 Kite Flies, But Durability Remains The Key Unknown
09/26 Array Plays Catch-Up In Braf-Mek Derby
09/26 BIOTECH FORUM DAILY DIGEST : Behind Some Big Moves In Small Caps. Spotlight On V..
09/26 Array Bio's encorafenib-binimetinib combo successful in late-stage melanoma s..
09/23 FDA OKs three new uses for Novartis' Ilaris
Advertisement
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 89,9 $
Spread / Average Target 12%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG-10.14%211 231
JOHNSON & JOHNSON16.06%322 232
ROCHE HOLDING LTD.-12.41%215 081
PFIZER INC.4.80%204 049
MERCK & CO., INC.18.46%171 858
GLAXOSMITHKLINE PLC19.26%103 357
More Results